PMID- 31839016
OWN - NLM
STAT- MEDLINE
DCOM- 20211115
LR  - 20211115
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Linking)
VI  - 51
IP  - 4
DP  - 2021 Mar
TI  - Calculating individualized risk components using a mobile app-based risk 
      calculator for clinical high risk of psychosis: findings from ShangHai At Risk 
      for Psychosis (SHARP) program.
PG  - 653-660
LID - 10.1017/S003329171900360X [doi]
AB  - BACKGROUND: Only 30% or fewer of individuals at clinical high risk (CHR) convert 
      to full psychosis within 2 years. Efforts are thus underway to refine risk 
      identification strategies to increase their predictive power. Our objective was 
      to develop and validate the predictive accuracy and individualized risk 
      components of a mobile app-based psychosis risk calculator (RC) in a CHR sample 
      from the SHARP (ShangHai At Risk for Psychosis) program. METHOD: In total, 400 
      CHR individuals were identified by the Chinese version of the Structured 
      Interview for Prodromal Syndromes. In the first phase of 300 CHR individuals, 196 
      subjects (65.3%) who completed neurocognitive assessments and had at least a 
      2-year follow-up assessment were included in the construction of an RC for 
      psychosis. In the second phase of the SHARP sample of 100 subjects, 93 with data 
      integrity were included to validate the performance of the SHARP-RC. RESULTS: The 
      SHARP-RC showed good discrimination of subsequent transition to psychosis with an 
      AUC of 0.78 (p < 0.001). The individualized risk generated by the SHARP-RC 
      provided a solid estimation of conversion in the independent validation sample, 
      with an AUC of 0.80 (p = 0.003). A risk estimate of 20% or higher had excellent 
      sensitivity (84%) and moderate specificity (63%) for the prediction of psychosis. 
      The relative contribution of individual risk components can be simultaneously 
      generated. The mobile app-based SHARP-RC was developed as a convenient tool for 
      individualized psychosis risk appraisal. CONCLUSIONS: The SHARP-RC provides a 
      practical tool not only for assessing the probability that an individual at CHR 
      will develop full psychosis, but also personal risk components that might be 
      targeted in early intervention.
FAU - Zhang, TianHong
AU  - Zhang T
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Xu, LiHua
AU  - Xu L
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Li, HuiJun
AU  - Li H
AD  - Department of Psychology, Florida A and M University, Tallahassee, Florida32307, 
      USA.
FAU - Woodberry, Kristen A
AU  - Woodberry KA
AD  - Harvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical 
      Center, 75 Fenwood Rd, Boston, MA02115, USA.
AD  - Center for Psychiatric Research, Maine Medical Center Research Institute, 
      Portland, Maine.
FAU - Kline, Emily R
AU  - Kline ER
AD  - Harvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical 
      Center, 75 Fenwood Rd, Boston, MA02115, USA.
FAU - Jiang, Jian
AU  - Jiang J
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Cui, HuiRu
AU  - Cui H
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Tang, YingYing
AU  - Tang Y
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Tang, XiaoChen
AU  - Tang X
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Wei, YanYan
AU  - Wei Y
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Hui, Li
AU  - Hui L
AD  - Institute of Mental Health, The Affiliated Guangji Hospital of Soochow 
      University, Soochow University, Suzhou215137, Jiangsu, China.
FAU - Lu, Zheng
AU  - Lu Z
AD  - Department of Psychiatry, Tongji Hospital, Tongji University, School of Medicine, 
      Shanghai, China.
FAU - Cao, LiPing
AU  - Cao L
AD  - Department of Early Intervention, Affiliated Brain Hospital of Guangzhou Medical 
      University (Guangzhou Huiai Hospital), Guangdong Engineering Technology Research 
      Center for Translational Medicine of Mental Disorders, Guangzhou510370, China.
FAU - Li, ChunBo
AU  - Li C
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
FAU - Niznikiewicz, Margaret A
AU  - Niznikiewicz MA
AD  - Harvard Medical School Department of Psychiatry, Veteran's Administration Medical 
      Center, Boston, MA02130, USA.
FAU - Shenton, Martha E
AU  - Shenton ME
AD  - Departments of Psychiatry and Radiology, Brigham and Women's Hospital, and 
      Harvard Medical School, and VA Boston Healthcare System, Boston, MA, USA.
FAU - Keshavan, Matcheri S
AU  - Keshavan MS
AD  - Harvard Medical School Department of Psychiatry, Veteran's Administration Medical 
      Center, Boston, MA02130, USA.
FAU - Stone, William S
AU  - Stone WS
AD  - Harvard Medical School Department of Psychiatry, Beth Israel Deaconess Medical 
      Center, 75 Fenwood Rd, Boston, MA02115, USA.
FAU - Wang, JiJun
AU  - Wang J
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiaotong University School of Medicine, Shanghai200030, China.
AD  - Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders 
      (Ministry of Education), Bio-X Institutes, Shanghai, China.
AD  - CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), 
      Chinese Academy of Science, Shanghai, China.
LA  - eng
GR  - R01 MH101052/MH/NIMH NIH HHS/United States
GR  - R01 MH111448/MH/NIMH NIH HHS/United States
GR  - R21 MH093294/MH/NIMH NIH HHS/United States
GR  - R21 MH113674/MH/NIMH NIH HHS/United States
GR  - K23 MH102358/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20191216
PL  - England
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
SB  - IM
MH  - China
MH  - Disease Progression
MH  - Humans
MH  - *Mobile Applications
MH  - Prodromal Symptoms
MH  - Psychiatric Status Rating Scales/*standards
MH  - Psychotic Disorders/*diagnosis
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Outcome
OT  - prediction
OT  - prodromal psychosis
OT  - transition
OT  - ultra high risk
EDAT- 2019/12/17 06:00
MHDA- 2021/11/16 06:00
CRDT- 2019/12/17 06:00
PHST- 2019/12/17 06:00 [pubmed]
PHST- 2021/11/16 06:00 [medline]
PHST- 2019/12/17 06:00 [entrez]
AID - S003329171900360X [pii]
AID - 10.1017/S003329171900360X [doi]
PST - ppublish
SO  - Psychol Med. 2021 Mar;51(4):653-660. doi: 10.1017/S003329171900360X. Epub 2019 
      Dec 16.